The information within this section of the website is intended for patients prescribed Prostap DCS. Members of the public, and UK Healthcare Professionals should follow the relevant links.

Prostap DCS: the pick of the bunch

indications-figure3

Therapeutic Indications2,3

Prostate cancer

  • Metastatic prostate cancer
  • Locally advanced prostate cancer, as an alternative to surgical castration
  • As an adjuvant treatment to radiotherapy in patients with high-risk localised or locally advanced prostate cancer
  • As an adjuvant treatment to radical prostatectomy in patients with locally advanced prostate cancer at high risk of disease progression
  • As neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced prostate cancer

Breast cancer

  • Treatment in pre- and perimenopausal women with advanced breast cancer suitable for hormonal manipulation

  • Adjuvant treatment in combination with tamoxifen or an aromatase inhibitor, of endocrine responsive early stage breast cancer in pre- and perimenopausal women at higher risk of disease recurrence (young age, high grade tumour, lymph node involvement)

Note: In women who have received chemotherapy, premenopausal status must be confirmed after completion of chemotherapy.

Endometriosis

  • Management of endometriosis, including pain relief and reduction of endometriotic lesions
  • Endometrial preparation prior to intrauterine surgical procedures (Prostap SR DCS only)
  • Preoperative management of uterine fibroids to reduce their size and associated bleeding (Prostap SR DCS only)

Preservation of ovarian function

  • Use in pre-menopausal women with neoplastic disease undergoing chemotherapy treatment that can cause premature ovarian insufficiency (Prostap SR DCS only)

NOTE: Treatment with a GnRH analogue should only be proposed after careful risk/benefit evaluation in each patient. Not a replacement for standard fertility-preservation methods.

Central precocious puberty

  • Central precocious puberty in girls under 9 years of age and boys under 10 years of age

Administration overview2,3

Intramuscular (IM) or subcutaneous (SC) administration is available, depending on indication and dose.

Dual Chamber Syringe

Leuprorelin is delivered in a Dual Chamber Syringe (DCS) system which allows administration in under a minute. abriefproductoverview-figure1

Needle size

Fine gauge needle abriefproductoverview-figure14

Image not to scale

Contact

If you are a healthcare professional and have a clinical query about Prostap DCS, please call Medical Information on:

01628 537 900

If you would like to find out more about how Prostap DCS can help your practice save money, or to order, please call CLARITYpharma on:

0845 080 5190

If you are a healthcare professional and would like to be contacted about Prostap DCS, please enter your details in the short form below

Your Name
Email
Phone
Definition of Role
Practice address
Postcode
*Required fields

Takeda UK Ltd will NOT share any of your details with any other parties. If at any time you wish to unsubscribe from receiving information about Prostap DCS, please call Takeda UK Ltd on 01628 537 900.

References

  1. Takeda UK Ltd. Data on file, DF120604(2)
  2. Prostap SR DCS, Summary of Product Characteristics.
  3. Prostap 3 DCS, Summary of Product Characteristics.
  4. NHS Electronic Drug Tariff. Part VIIIA products L. Available at: http://www.drugtariff.nhsbsa.nhs.uk/#/00280039-DC/DC00279755/PartVIIIA (last accessed July 2019).
  5. NHS Data April 2019, HPA May 2019.

This part of the Prostap® DCS (leuprorelin acetate) online resource is specifically for Practice Managers. If you are not a Practice Manager, please select the appropriate area of this website from the welcome page.

No

I am not a Practice Manager

Yes

I am a Practice Manager

This part of the Prostap® DCS (leuprorelin acetate) online resource is specifically for Healthcare Professionals.

If you are not a Healthcare Professional, please select NO to go back and select the appropriate section of this website for you.

No

I am not a
Healthcare Professional

Yes

I am a Healthcare Professional interested in prostate cancer

Yes

I am a Healthcare Professional interested in endometriosis

Yes

I am a Healthcare Professional interested in breast cancer

This part of the Prostap® DCS (leuprorelin acetate) online resource is specifically for patients who have been prescribed Prostap DCS.

If you are not a patient who has been prescribed Prostap DCS, please select the appropriate area of this website from the welcome page.

No

I am not a Prostap DCS prescribed patient.

Yes

I am a Prostap DCS prescribed patient.